Overview


According to FutureWise analysis the market for intranasal drug delivery devices in 2023 is US$ 1.69 billion, and is expected to reach US$ 4.74 billion by 2031 at a CAGR of 13.72%.

Numerous germs and microbes can enter the body through various mucosal locations and cause a new infection. There are currently a large number of parenterally administered vaccines on the market. They are capable of developing high immunity, but not mucosal immunity. Nasal vaccines are widely used to provide a foundation of protection against pathogens that enter through the mucus. Administration through mucosal locations, particularly the nasal route, adds to the list of promising and alternate vaccination and medication delivery methods. These methods have a variety of advantages that aid in the treatment of a variety of diseases. Several prominent players are working on developing novel medicines and other devices for vaccination delivery via the nasal route. Furthermore, many evidences aid in the safe administration of medications and vaccinations via the nasal route. Although there have been some concerns about the nasal delivery of medications and vaccinations in recent years, this area of healthcare has been rapidly expanding. hrough the creation of spontaneous patient-friendly modernizations, intranasal drug delivery systems and apparatuses enable therapies to remain cutting-edge while also improving the lives of affected persons, providing a bright future for the company's total business. Innovative techniques to circumvent biological blockades to delivery are being developed in order to fully benefit from the possibilities given by nasal delivery of drugs.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Intranasal Drug Delivery Devices Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Intranasal Drug Delivery Devices Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Johnson and Johnson, Inc.
  • Aptar Pharma Group
  • GlaxoSmithKline Plc.
  • Aegis Therapeutics LLC.
  • H T Presspart Manufacturing Ltd.
  • AstraZeneca Plc.
  • Becton, Dickinson and Company
  • Novartis AG
  • Teleflex Incorporated
  • Vectura Group Plc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By System

  • Metered Dose
  • Multi-Dose Systems
  • Unit-Dose Systems

By Container

  • Non-Pressurized Containers
  • Pressurized Containers

By Application

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Rhinitis
  • Cystic Fibrosis
  • Nasal Congestion
  • Asthma
  • Others

By End User

  • Ambulatory Surgical Centers
  • Clinics
  • Hospitals
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Intranasal Drug Delivery Devices Market By System, By Container, By Application, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Intranasal Drug Delivery Devices Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Intranasal Drug Delivery Devices Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Intranasal Drug Delivery Devices Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Intranasal Drug Delivery Devices Market, By System Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Metered Dose
        2. Multi-Dose Systems
        3. Unit-Dose Systems

  • 8.   Intranasal Drug Delivery Devices Market, By Container Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Non-Pressurized Containers
        2. Pressurized Containers

  • 9.   Intranasal Drug Delivery Devices Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Chronic Obstructive Pulmonary Disease (COPD)
        2. Rhinitis
        3. Cystic Fibrosis
        4. Nasal Congestion
        5. Asthma
        6. Others

  • 10.   Intranasal Drug Delivery Devices Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Ambulatory Surgical Centers
        2. Clinics
        3. Hospitals
        4. Others

  • 11.   North America Intranasal Drug Delivery Devices Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Intranasal Drug Delivery Devices Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Intranasal Drug Delivery Devices Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Intranasal Drug Delivery Devices Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.  Johnson, Inc.
    •   1. Johnson and Johnson, Inc.
                   1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Aptar Pharma Group
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. GlaxoSmithKline Plc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Aegis Therapeutics LLC.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. H T Presspart Manufacturing Ltd.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. AstraZeneca Plc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Becton, Dickinson and Company
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Novartis AG
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Teleflex Incorporated
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Vectura Group Plc.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients